won won - Academia.edu (original) (raw)
Papers by won won
This is an Open Access article distributed under the terms of the Creative Commons Attribution No... more This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
Nephrology Dialysis Transplantation, 2007
Background. Renin-angiotensin system (RAS) blockades, angiotensin converting enzyme inhibitors (A... more Background. Renin-angiotensin system (RAS) blockades, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are well accepted for the cardiorenal-protective benefits added to antihypertensive effects in chronic kidney diseases (CKD), but associated with an increased risk of hyperkalaemia. However, few studies have investigated the effect of RAS blockades on serum potassium in dialysis patients. Methods. Hyperkalaemia associated with RAS blockades by ACEI and/or ARB was evaluated in 69 patients on maintenance haemodialysis, who underwent a three-period crossover study in four groups (no exposure to RAS blockades, ACEI or ARB alone and ACEI plus ARB treatments), lasting one month in each period. Results. Sixty-two patients completed this prospective 3-month study, and no one stopped the study because of the development of hyperkalaemia and/or complications. Mean serum K was similar among the four periods (no exposure, 5.54 AE 0.67 mmol/l; ACEI alone, 5.54 AE 0.75 mmol/l; ARB alone, 5.50 AE 0.66 mmol/l; ACEI þ ARB combination, 5.42 AE 0.66 mmol/l) and was also equal when compared between the two groups with and without exposure to RAS blockades (5.48 AE 0.68 vs 5.54 AE 0.67 mmol/l, P ¼ NS). The incidence of severe hyperkalaemic episodes (>6.0 mmol/l) upon monthly predialysis serum K determination was 25.8% with no exposure to RAS blockades, 29.8% for ACEI alone, 19.6% for ARB alone and 17.7% for ACEI þ ARB combination without statistically significant differences among the four periods (P ¼ NS). Among covariables, the degree of Kt/V, intakes of other medications interfering with potassium homeostasis and diabetes mellitus did not result in any significant hyperkalaemic changes during the 3-month study period except anuric patients compared with non-anuric patients (5.58 AE 0.69 vs 5.19 AE 0.65 mmol/l, P < 0.001). Conclusion. Neither monotherapy (ACEI or ARB) nor combination therapy (ACEI plus ARB) is associated with the additional risk of hyperkalaemia in patients on maintenance haemodialysis. However, those patients with anuria on RAS blockades warrant the cautious monitoring of serum K to prevent hyperkalaemia.
Nephrology Dialysis Transplantation, 2006
Journal of the Korean Physical Society, 2007
We measured isomeric cross-section ratios for the Sc-45(gamma,n)(SC)-S-44m,g, Ti-nat (gamma,x)(SC... more We measured isomeric cross-section ratios for the Sc-45(gamma,n)(SC)-S-44m,g, Ti-nat (gamma,x)(SC)-S-44m,g, Rh-103(gamma,4n)Rh-99m,Rh-g, and Fe-nat(gamma,x)Mn-52m,Mn-g reactions at the 65-MeV electron linac of the Po-hang Accelerator Laborator by using the activation method. Samples of natural Sc, Ti, Rh, and Fe metallic foils were irradiated in an uncollimated bremsstrahlung beam. The isomeric cross-section ratios were determined from the activity measurement with a high-purity germanium detector. The measured isomeric ratios were 0.21 +/- 0.03, 0.12 +/- 0.03, 1.43 +/- 0.20, and 0.28 +/- 0.04 for the Sc-45(gamma,n)Sc-44m,Sc-g, Ti-nat (gamma,x)Sc-44m,Sc-g, Rh-103(gamma,4n)Rh-99m,Rh-g, and Fe-nat(gamma,x)Mn-52m,Mn-g reactions, respectively. The present results for the Sc-45(gamma,n)Sc-44m,Sc-g and Fe-nat(gamma,x)Mn-52m,Mn-g reactions are in good agreement with other measurements. The present results for Ti-nat(gamma,x)(44m,g) Sc and Rh-103(gamma,4n)Rh-99m,Rh-g reactions are the first such measurements.11sciescopuskc
European Journal of Anaesthesiology, 2008
Archives of Pharmacal Research, 1988
Apigenin, apigenin-7-O-glucoside, luteolin-7-O-glucoside and linarin were isolated fromElscholtzi... more Apigenin, apigenin-7-O-glucoside, luteolin-7-O-glucoside and linarin were isolated fromElscholtzia cristata (Labiatae).
Archives of Pharmacal Research, 1988
Apigenin, apigenin-7-O-glucoside, luteolin-7-O-glucoside and linarin were isolated fromElscholtzi... more Apigenin, apigenin-7-O-glucoside, luteolin-7-O-glucoside and linarin were isolated fromElscholtzia cristata (Labiatae).
This is an Open Access article distributed under the terms of the Creative Commons Attribution No... more This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
Nephrology Dialysis Transplantation, 2007
Background. Renin-angiotensin system (RAS) blockades, angiotensin converting enzyme inhibitors (A... more Background. Renin-angiotensin system (RAS) blockades, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are well accepted for the cardiorenal-protective benefits added to antihypertensive effects in chronic kidney diseases (CKD), but associated with an increased risk of hyperkalaemia. However, few studies have investigated the effect of RAS blockades on serum potassium in dialysis patients. Methods. Hyperkalaemia associated with RAS blockades by ACEI and/or ARB was evaluated in 69 patients on maintenance haemodialysis, who underwent a three-period crossover study in four groups (no exposure to RAS blockades, ACEI or ARB alone and ACEI plus ARB treatments), lasting one month in each period. Results. Sixty-two patients completed this prospective 3-month study, and no one stopped the study because of the development of hyperkalaemia and/or complications. Mean serum K was similar among the four periods (no exposure, 5.54 AE 0.67 mmol/l; ACEI alone, 5.54 AE 0.75 mmol/l; ARB alone, 5.50 AE 0.66 mmol/l; ACEI þ ARB combination, 5.42 AE 0.66 mmol/l) and was also equal when compared between the two groups with and without exposure to RAS blockades (5.48 AE 0.68 vs 5.54 AE 0.67 mmol/l, P ¼ NS). The incidence of severe hyperkalaemic episodes (>6.0 mmol/l) upon monthly predialysis serum K determination was 25.8% with no exposure to RAS blockades, 29.8% for ACEI alone, 19.6% for ARB alone and 17.7% for ACEI þ ARB combination without statistically significant differences among the four periods (P ¼ NS). Among covariables, the degree of Kt/V, intakes of other medications interfering with potassium homeostasis and diabetes mellitus did not result in any significant hyperkalaemic changes during the 3-month study period except anuric patients compared with non-anuric patients (5.58 AE 0.69 vs 5.19 AE 0.65 mmol/l, P < 0.001). Conclusion. Neither monotherapy (ACEI or ARB) nor combination therapy (ACEI plus ARB) is associated with the additional risk of hyperkalaemia in patients on maintenance haemodialysis. However, those patients with anuria on RAS blockades warrant the cautious monitoring of serum K to prevent hyperkalaemia.
Nephrology Dialysis Transplantation, 2006
Journal of the Korean Physical Society, 2007
We measured isomeric cross-section ratios for the Sc-45(gamma,n)(SC)-S-44m,g, Ti-nat (gamma,x)(SC... more We measured isomeric cross-section ratios for the Sc-45(gamma,n)(SC)-S-44m,g, Ti-nat (gamma,x)(SC)-S-44m,g, Rh-103(gamma,4n)Rh-99m,Rh-g, and Fe-nat(gamma,x)Mn-52m,Mn-g reactions at the 65-MeV electron linac of the Po-hang Accelerator Laborator by using the activation method. Samples of natural Sc, Ti, Rh, and Fe metallic foils were irradiated in an uncollimated bremsstrahlung beam. The isomeric cross-section ratios were determined from the activity measurement with a high-purity germanium detector. The measured isomeric ratios were 0.21 +/- 0.03, 0.12 +/- 0.03, 1.43 +/- 0.20, and 0.28 +/- 0.04 for the Sc-45(gamma,n)Sc-44m,Sc-g, Ti-nat (gamma,x)Sc-44m,Sc-g, Rh-103(gamma,4n)Rh-99m,Rh-g, and Fe-nat(gamma,x)Mn-52m,Mn-g reactions, respectively. The present results for the Sc-45(gamma,n)Sc-44m,Sc-g and Fe-nat(gamma,x)Mn-52m,Mn-g reactions are in good agreement with other measurements. The present results for Ti-nat(gamma,x)(44m,g) Sc and Rh-103(gamma,4n)Rh-99m,Rh-g reactions are the first such measurements.11sciescopuskc
European Journal of Anaesthesiology, 2008
Archives of Pharmacal Research, 1988
Apigenin, apigenin-7-O-glucoside, luteolin-7-O-glucoside and linarin were isolated fromElscholtzi... more Apigenin, apigenin-7-O-glucoside, luteolin-7-O-glucoside and linarin were isolated fromElscholtzia cristata (Labiatae).
Archives of Pharmacal Research, 1988
Apigenin, apigenin-7-O-glucoside, luteolin-7-O-glucoside and linarin were isolated fromElscholtzi... more Apigenin, apigenin-7-O-glucoside, luteolin-7-O-glucoside and linarin were isolated fromElscholtzia cristata (Labiatae).